Metastatic Brain Tumor Clinical Trial
Official title:
Does Cognitive Rehabilitation and Physical Activity Impact Executive Functioning Following Radiation Therapy for Cerebral Metastases? A Pilot Study
To determine the feasibility of processes and instruments with an overarching purpose to guide the design of a larger study. To determine the feasibility of individuals with metastatic brain tumor(s) to engage in physical activity(PA) and cognitive rehabilitation (CR) as in an outpatient therapy setting.
Rolling recruitment for the study. Participants will be randomized into one of three treatment arms. All treatment arms will undergo physical & cognitive testing prior to whole-brain radiation therapy (WBRT)/stereotactic radiosurgery (SRS). Arm 3 will receive cognitive rehabilitation intervention sessions prior to, and concurrent with, WBRT/SRS. Approximately 14 days following WBRT/SRS: all arms will undergo physical and cognitive testing, and: Arm 1 will begin physical activity intervention. Arm 2 will begin physical activity intervention and cognitive intervention. Arm 3 will continue with cognitive intervention and begin physical activity intervention. All Arms will undergo physical and cognitive testing approximately 2.5 months post WBRT/SRS. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT05559853 -
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
|
||
Completed |
NCT02392078 -
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
|
||
Recruiting |
NCT05288439 -
A Study of How Proton Beam Radiotherapy (PBRT) Affects Brain Function and Quality of Life in Children and Young Adults Undergoing Treatment for a Brain Tumor
|
N/A | |
Not yet recruiting |
NCT05839379 -
Targeted Pediatric High-Grade Glioma Therapy
|
||
Not yet recruiting |
NCT05843253 -
Study of Ribociclib and Everolimus in HGG and DIPG
|
Phase 2 | |
Not yet recruiting |
NCT06161974 -
Study of Olutasidenib and Temozolomide in HGG
|
Phase 2 | |
Recruiting |
NCT01535430 -
Assessment of Eloquent Function in Brain Tumor Patients
|
||
Recruiting |
NCT01908179 -
Markers of Prognosis and Response to Therapy in Patients With Metastatic Brain Tumors Undergoing Stereotactic Radiosurgery (SRS)
|
N/A |